Steroid Avoidance or Withdrawal After Renal Transplantation Increases the Risk of Acute Rejection but Decreases Cardiovascular Risk. A Meta-Analysis
The DOI matches its Crossref record; 112 of the 113 references it cites were found in a registry or an index.
Abstract
Introduction The morbidity related to long-term steroid therapy has led to continued interest in withdrawal of steroids from immunosuppressant regimens after renal transplantation. A number of recent trials have provided long-term information regarding the risks and benefits of steroid avoidance or withdrawal (SAW). Methods A literature search was performed using Ovid Medline, Embase, the Cochrane Library, and the Transplant Library. Randomized controlled trials comparing a maintenance steroid group with complete avoidance or withdrawal of steroids were selected. All studies were assessed for methodological quality. Trials were pooled by meta-analysis to provide summary effects (relative risk [RR] or weighted mean difference) with 95% confidence intervals (CI). Results Thirty-four studies including 5,637 patients met the inclusion criteria. SAW regimens significantly increased the risk of acute rejection (AR) over maintenance steroids (RR 1.56, CI 1.31-1.87, P Conclusion Despite an increase in the risk of AR with SAW protocols, there is only a small effect on graft function with no measurable effect on graft or patient survival. There are significant benefits in cardiovascular risk profiles after SAW. SAW protocols would seem justified with current immunosuppressive protocols in low-risk recipients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Other more unique risk factors in this population include genetic polymorphisms, polycystic kidney disease, hepatitis C, and cytomegalovirus status.1579–1581”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1579]
In the citing paper
“An increasing body of new literature points to the association of immune checkpoint inhibitors with new-onset hyperglycemia and DM.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1579]
In the citing paper
“At this time, most of the literature is in the form of case reports demonstrating hyperglycemia, new-onset diabetes, and DKA, either with or without autoimmune markers of T1D.1579,1600–1605”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1579]
Citations
Cites
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763 · cited 1×
“Heterogeneity was quantified using the I(2) test, which describes the percentage of total variation across the studies that is due to heterogeneity rather than chance (17).”
MethodAssessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582 · cited 1×
“Quality was assessed both by means of the Jadad score (a score of 3 or greater is considered good quality) and a description of allocation concealment and analysis based on intention-totreat (15).”
MethodParmar, M. K. B., Torri, V., & Stewart, L. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8 · Cited by 4,802 · cited 2×
“2 (46) 57±20 (25) 66±33 (42) 47±17 (49) Maintenance Mean ± sd (N) 58.”
MethodInteraction revisited: the difference between two estimates.
Altman, D. G., & Bland, J. M. (2003) · BMJ · doi:10.1136/bmj.326.7382.219 · Cited by 3,203 · cited 2×
“Subgroups were compared using the interaction method described by Altman and Bland (28), with a significance level of P less than 0.”
InfluentialRosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
Fellström, B. C., Jardine, A. G., Schmieder, R. E., Holdaas, H., Bannister, K., Beutler, J., Chae, D.-W., Chevaile, A., Cobbe, S. M., Grönhagen-Riska, C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810177 · Cited by 2,036 · cited 3×
“2 (42) 161±65 (44) Maintenance Mean ± sd (N) 184.”
ResultImputing missing standard deviations in meta-analyses can provide accurate results
Furukawa, T. A., Barbui, C., Cipriani, A., Brambilla, P., & Watanabe, N. (2006) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2005.06.006 · Cited by 1,568 · cited 1×
“Otherwise, a pooled standard deviation was calculated for all similar studies in the current meta-analysis and applied to studies with missing values (27).”
MethodLong-term survival in renal transplant recipients with graft function
Ojo, A. O., Hanson, J. A., Wolfe, R. A., Leichtman, A. B., Agodoa, L. Y., & Port, F. K. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00816.x · Cited by 810 · cited 2×
“Death with a functioning graft is an important cause of graft loss after renal transplantation, accounting for more than 40% of graft losses in one registry analysis (2).”
BackgroundWoodle, E. S., First, M. R., Pirsch, J., Shihab, F., Gaber, A. O., & Van Veldhuisen, P. (2008) · Annals of Surgery · doi:10.1097/sla.0b013e318187d1da · Cited by 474
A Meta-Analysis of Immunosuppression Withdrawal Trials in Renal Transplantation
KASISKE, B. L., CHAKKERA, H. A., LOUIS, T. A., & MA, J. Z. (2000) · Journal of the American Society of Nephrology · doi:10.1681/asn.v11101910 · Cited by 392
Experience in Renal Transplantation
Starzl, T. E. (1965) · The American Journal of the Medical Sciences · doi:10.1097/00000441-196505000-00064 · Cited by 363
Research works printed but not linked: 41
- Tan, 2006, Safety and efficacy of steroid withdrawal in modern triple immunosuppressant: A systematic review [Chinese]., Chin J Evid Based Med, 6, 273
- Vincenti, 2005, 3 months interim results of a 12-month study with enteric-coated mycophenolate sodium (EC-MPS, Myfortic®), basiliximab, and neoral C-2 comparing different steroid protocols in de novo kidney recipients [abstract]., J Am Soc Nephrol, 16, 236a
- Walker, 2005, Preliminary results of a 12-month study with enteric-coated mycophenolate sodium (EC-MPS), basiliximab, and neoral C-2 comparing two investigational steroid regimens (without steroids or short-term use of steroids) with standard steroid treatment in de novo kidney recipients [abstract]., Nephrology, 10, A214
- Vincenti, 2006, Metabolic effects of steroid avoidance or early steroid withdrawal: 12-month results of a randomised trial in de novo renal transplant patients receiving cyclosporine, enteric-coated mycophenolate sodium (EC-MPS) and basiliximab [abstract]., Am J Transplant, 6, 483
- Schena, 2006, 12-month results of a prospective, randomised trial of steroid avoidance, steroid withdrawal and standard steroids in de novo renal transplant patients receiving cyclosporine, enteric-coated mycophenolate sodium (EC-MPS) and basiliximab [abstract]., Am J Transplant, 6, 84
- Vincenti, 2005, Preliminary 3-month results comparing immunosuppressive regimens of enteric-coated mycophenolate sodium (EC- MPS) without steroids vs short-term use of steroids vs standard steroid treatment including basiliximab, and neoral C-2 in de novo kidney recipients abstract., Am J Transplant, 5, 548
- Walker, 2007, Comparison of metabolic parameters in renal transplant patients randomised to steroid avoidance, steroid withdrawal or standard steroids within a 12 month randomised multicentre trial [abstract]., Transplant Soc Aust N Z, 32
- Ing, 2007, Bone mineral density changes in a prospective randomized trial of steroid withdrawal in kidney transplant recipients abstract., Am J Transplant, 7, 310
- Stiller, 1983, The requirements for maintenance steroids in cyclosporine-treated renal transplant recipients., Transplant Proc, 15, 2490
- De Vecchi, 1985, Need for steroid in cyclosporine (Cy) treated cadaveric renal transplant recipients (pts) [abstract]., Kidney Int, 28, 394
- Griffin, 1986, Renal transplantation without steroids: A controlled clinical trial., Transplant Proc, 18, 797
- Nott, 1985, Low-dose steroids do not augment cyclosporine immunosuppression but do diminish cyclosporine nephrotoxicity., Transplant Proc, 17, 1289
- Johnson, 1990, Prospective trials with cyclosporine monotherapy in cadaver renal transplantation., J Nephrol, 3, 47
- Tarantino, 2000, Long-term results of a randomized trial of 3 cyclosporine (CSA) regimens in cadaveric kidney allografts (TXC) [abstract]., Nephrol Dial Transplant, 15, 250
- Klinger, 2003, Large, prospective study evaluating steroid-free immunosuppression with tacrolimus/basiliximab and tacrolimus/MMF compared with tacrolimus/MMF/steroids in renal transplantation [abstract]., Nephrol Dial Transplant, 18, 788
- Kramer, 2003, Two steroid-free immunosuppressive regimens (basiliximab/tacrolimus and tacrolimus/MMF) in comparison to tacrolimus/MMF/steroid therapy after renal transplantation [abstract]., J Am Soc Nephrol, 14, 9a
- Kramer, 2004, 1-year follow-up of two steroid-free immunosuppressive regimens—Basiliximab/Tacrolimus and tacrolimus/MMF—In comparison to tacrolimus/MMF/steroids after renal transplantation [abstract]., J Am Soc Nephrol, 15, 289a
- Vitko, 2003, Comparison of two steroid-free regimens—Basiliximab/Tacrolimus and Tacrolimus/MMF—With Tacrolimus/MMF/Steroid Therapy After Renal Transplantation [abstract]., Am J Transplant, 3, 312
- Pankewycz, 2004, The clinical benefits of early steroid withdrawal (7 days) and utility of protocol biopsies at 1, 6 and 12 months in guiding steroid-free immunosuppressive therapy after renal transplantation [abstract]., Am J Transplant, 4, 579
- Pankewyez, 2003, Induction immunosuppression for renal transplantation using thymoglobulin, FK506 and mycophenolate mofetil allows for safe steroid withdrawal and eliminates the need for early protocol biopsies [abstract]., Am J Transplant, 3, 478
- Gaber, 2006, Characteristics of rejection in renal allografts following early corticosteroid withdrawal in a randomized controlled clinical trial: Results of a 3 year follow-up [abstract]., Transplantation, 82, 178
- Pirsch, 2006, Effect of steroid withdrawal on new onset diabetes after transplant: Results of a randomized double blinded placebo controlled trial [abstract]., Transplantation, 82, 355
- Woodle, 2007, A randomized double blind, placebo-controlled trial of early corticosteroid cessation versus chronic corticosteroids: Four year results [abstract]., Am J Transplant, 7
- Woodle, 2006, Comparison of T cell depleting and non-t cell depleting antibody induction therapy for early corticosteroid withdrawal regimens abstract., Transplantation, 82, 353
- Woodle, 2008, A randomsied double blind, placebo-controlled trial of early corticosteroid cessation versus chronic corticosteroids: Five year results., Am J Transplant, 8, 300
- Nematalla, 2007, Improving quality of life after steroid avoidance immunosuppression regimen in live donor renal allotransplant recipients—A prospective randomized controlled study single center experience (Two year follow up) [abstract]., Transpl Int, 20, 134
- Aswad, 1998, Steroid withdrawal in living related kidney transplant patients receiving FK506 [abstract]., Nephrol Dial Transplant, 13, A285
- Burke, 2001, Double-blind, placebo-controlled trial of steroid withdrawal in kidney transplant recipients with a cyclosporine/mycophenolate regimen-three year follow up [abstract]., Am J Transplant, 1, 296
- Francos, 2002, Double-blind, placebo-controlled, 3 year study of steroid withdrawal using a neoral and mycophenylate mofetil (MMF)-based immunosuppressive regimen in primary renal transplant recipients [abstract]., Am J Transplant, 2, 172
- Boletis, 2002, Steroids withdrawal in renal transplant recipients: A randomized controlled study [abstract]., Nephrol Dial Transplant, 17, 312
- Smak Gregoor, 2001, A prospective randomised study of withdrawal of cyclosporine or prednisone in renal transplant recipients treated with mycophenolate mofetil, cyclosporine, and prednisone: 18 months follow-up data [abstract]., Am J Transplant, 1, 246
- Smak Gregoor, 2003, Long-term results of a randomized, prospective study after withdrawal of cyclosporine or prednisone in renal transplant recipients treated with mycophenolate mofetil, cyclosporine, and prednisone [abstract]., Am J Transplant, 3, 217
- Jindal, 2002, Reduction of high cholesterol levels by early withdrawal of steroids from a tacrolimus-based triple regimen [abstract]., Am J Transplant, 2, 190
- Pascual, 2004, Long-term efficacy and safety of steroid withdrawal in tacrolimus-treated renal transplant recipients: Results of a 3 year followup., Am J Transplant, 4, 578
- van Hooff, 2001, First, large, prospective study of a controlled withdrawal of steroids or MMF following three months of tacrolimus/MMF/steroid therapy abstract., J Am Soc Nephrol, 12, 920a
- Dudley, 1994, Effect of steroid withdrawal on graft function in renal transplant recipients [abstract]., Nephrol Dial Transplant, 9, 1672
- Hollander, 1996, Late prednisone withdrawal in renal transplant patients [abstract]., J Am Soc Nephrol, 7, 1911
- Matl, 2000, Withdrawal of steroids from the triple-drug therapy in renal transplant patients., Casopis Lekaru Ceskych, 139, 115
- Matl, 1998, Withdrawal of steroids from triple drug therapy in renal transplant patients [abstract]., Nephrol Dial Transplant, 13, A256
- Farmer, 2001, What is the value of short synacthen tests in predicting the ease of steroid withdrawal in renal transplant recipients? A randomised controlled trial [abstract]., Am J Transplant, 1, 190
- Akin, 2004, Five year follow-up after steroid withdrawal demonstrates no evidence of worsening renal function [abstract]., Am J Transplant, 4, 298
Cited by
Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003480 · Cited by 3,473
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Diagnosis and prevention of chronic kidney allograft loss
Nankivell, B. J., & Kuypers, D. R. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60699-5 · Cited by 324
Prevention of cardiovascular disease in adult recipients of kidney transplants
Jardine, A. G., Gaston, R. S., Fellstrom, B. C., & Holdaas, H. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61334-2 · Cited by 281
Steroid avoidance or withdrawal for kidney transplant recipients
Haller, M. C., Royuela, A., Nagler, E. V., Pascual, J., & Webster, A. C. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005632.pub3 · Cited by 258
Metadata
- Authors
- Knight, S. R., & Morris, P. J.
- Affiliations
- University of London (GB)
- Corresponding author
- Morris, Peter J.
- ORCID
- Knight, Simon R.
- Venue
- Transplantation
- Published
- 2010-01-15
- Volume
- 89
- Issue
- 1
- Pages
- 1-14
- ISSN
- 0041-1337 (ISSN-L)
- OpenAlex
- W2006211317
- Cited by
- 265
- References
- 113
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 8 · 2023: 14 · 2022: 11 · 2021: 14 · 2020: 10 · 2019: 15 · 2018: 13 · 2017: 17 · 2016: 25 · 2015: 20 · 2014: 26 · 2013: 16 · 2012: 21
- FWCI
- 4.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Transplantation (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Health Sciences › Medicine › Nephrology › Renal and Vascular Pathologies
- Keywords
- steroid avoidance, corticosteroid withdrawal, kidney transplantation, acute rejection, corticosteroid-sparing immunosuppression, cardiovascular risk, hypertension, new-onset diabetes, hypercholesterolemia, graft survival, patient survival, serum creatinine
- MeSH terms
- Adrenal Cortex Hormones, Cardiovascular Diseases, Graft Rejection, Humans, Immunosuppressive Agents, Meta-Analysis as Topic, Kidney Transplantation, Survivors, Patient Selection
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Steroid Avoidance or Withdrawal After Renal Transplantation Increases the Risk of Acute Rejection but Decreases Cardiovascular Risk. A Meta-Analysis. https://app.cochat.ai/papers/10.1097/tp.0b013e3181c518cc
- The paper
- Knight, S. R., & Morris, P. J. (2010). Steroid Avoidance or Withdrawal After Renal Transplantation Increases the Risk of Acute Rejection but Decreases Cardiovascular Risk. A Meta-Analysis. Transplantation. https://doi.org/10.1097/tp.0b013e3181c518cc
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.